NEWARK, Calif., June 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $30.50 per share pursuant to a registration statement filed with the Securities and Exchange Commission (SEC). All of the shares in the offering are to be sold by Revance. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 600,000 shares from Revance. The offering is expected to close on June 24, 2014, subject to customary closing conditions.
Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering, with BMO Capital Markets and William Blair acting as co-managers.
The offering will be made only by means of a prospectus, copies of which may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: email@example.com.
A registration statement relating to these securities has been filed with the SEC and was declared effective by the SEC on June 18, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Revance's expectations regarding the completion of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Revance will be able to raise capital through the sale of shares of common stock, the final terms of the public offering, market and other conditions, the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Revance will be able to complete the public offering on the anticipated terms, or at all. Revance will need to raise additional capital to fund its operations and may be unable to raise capital when needed, which would force Revance to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the public offering, Revance and its business can be found under the heading "Risk Factors" in the prospectus included in Revance's Registration Statement on Form S-1 (File No. 333-196582), initially filed with the SEC on June 6, 2014, as amended. Revance expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
CONTACT: Westwicke Partners, Investor Relations Lynn Pieper 415-202-5678 firstname.lastname@example.orgSource:Revance Therapeutics, Inc.